Emerging drugs for head and neck cancer

Expert Opinion on Emerging Drugs

Volumn 20, Issue 2, 2015, Pages 313-329

  Wen, Yihui ^a,b,c   Grandis, Jennifer R ^c,d,e  

^a THE FIRST AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY   (China)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d University of Pittsburgh School of Medicine   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cetuximab; Chemotherapy; Clinical trial; Drugs resistance; Epidermal growth factor receptor; Gene therapy; Head and neck cancer; Immunotherapy; Squamous cell carcinoma; The Cancer Genome Atlas

Indexed keywords

AFATINIB; ANTINEOPLASTIC AGENT; CETUXIMAB; GEFITINIB; IMMUNOMODULATING AGENT; LAPATINIB; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MONOCLONAL ANTIBODY; NIMOTUZUMAB; PROGRAMMED DEATH 1 LIGAND 1; PROTEIN TYROSINE KINASE INHIBITOR; SOMATOMEDIN C RECEPTOR; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; ZALUTUMUMAB;

CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RESEARCH; CANCER SURVIVAL; GENE THERAPY; HEAD AND NECK CANCER; HUMAN; MOLECULARLY TARGETED THERAPY; OVERALL SURVIVAL; REVIEW; ANIMAL; CARCINOMA, SQUAMOUS CELL; DRUG APPROVAL; DRUG DESIGN; DRUG RESISTANCE; GENETICS; HEAD AND NECK NEOPLASMS; PATHOLOGY; SURVIVAL RATE;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; DRUG APPROVAL; DRUG DESIGN; DRUG RESISTANCE, NEOPLASM; HEAD AND NECK NEOPLASMS; HUMANS; MOLECULAR TARGETED THERAPY; SURVIVAL RATE;

EID: 84930026938     PISSN: 14728214     EISSN: 17447623     Source Type: Journal    
DOI: 10.1517/14728214.2015.1031653     Document Type: Review

References (149)

1. Denaro N, Russi EG, ADamo V, MerLano MC. State-of-The-Art and emerging treatment options in the management of head and neck cancer: news from 2013. Oncology 2014;86:212-29
2. FerLay J, Shin HR, Bray F, et al. Estimates of worldwiDe burDen of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893-917
3. Albers AE, Strauss L, Liao T, et al. T cell-tumor interaction directs the Development of immunotherapies in head and neck cancer. Clin Dev Immunol 2010;2010:236378
4. HadDad RI, Shin DM. Recent adVances in head and neck cancer. N Engl J Med 2008;359:1143-54
5. Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010;363:24-35
6. Price KA, Cohen EE. Current treatment options for metastatic head and neck cancer. Curr Treat Options Oncol 2012;13:35-46
7. Purohit S, Bhise R, Lokanatha D, Govindbabu K. Systemic therapy in head and neck cancer: changing paradigm. Indian J Surg Oncol 2013;4:19-26
8. Browman GP, Cronin L. StanDard chemotherapy in squamous cehead and neck cancer: what we have learned from randomized trials. Semin Oncol 1994;21:311-19
9. Brockstein B, Haraf DJ, RaDemaker AW, et al. Patterns of failure, prognostic factors and survival in locoregionally adVanced head and neck cancer treated with concomitant chemoradiotherapy: A 9-year, 337-patient, multi-institutional experience. Ann Oncol 2004;15:1179-86
10. ChanDana SR, Conley BA. NeoadjuVant chemotherapy for locally adVanced squ mous cancers of the head and neck: current status and future prospects. Curr Opin Oncol 2009;21:218-23
11. Qin H, Luo J, Zhu YP, et al. Combination of taxanes, cispLatin and fluorouracil as induction chemotherapy for locally adVanced head and neck cancer: A meta-Analysis. PLoS One 2012;7:e51526
12. Minicucci EM, Da Silva GN, Salvadori DM. ReLationship between head and neck cancer therapy and some genetic endpoints. World J Clin Oncol 2014;5:93-102
13. Pui CH, Relling MV. Can the genotoxicity of chemotherapy be predicted? Lancet 2004;364:917-18
14. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cecarcinoma of the head and neck. N Engl J Med 2006;354:567-78
15. Vermorken JB, Trigo J, Hitt R, et al. Open-Label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cecarcinoma of the head and neck who failed to respond to pLatinum-based therapy. J Clin Oncol 2007;25:2171-7
16. Vermorken JB, Mesia R, Rivera F, et al. PLatinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008;359:1116-27
17. National Comprehensive Cancer Network. NCCN clinical practice guiDelines in oncology. Head and Neck Cancers. V.2. 2014. AvaiLable from: https://www.nccn. org/store/login/login.aspx? ReturnURL=http://www.nccn.org/professionals/physician-gls/pdf/head-Andneck.Pdf
18. Li S, Schmitz KR, Jeffrey PD, et al. Structural basis for inhibition of the epiDermal growth factor receptor by cetuximab. Cancer Ce2005;7:301-11
19. Lopez-Albaitero A, Lee SC, Morgan S, et al. Role of polymorphic Fc gamma receptor IIIa and EGFR expression level in cetuximab mediated, NK ceDepenDent in vitro cytotoxicity of head and neck squamous cecarcinoma cells. Cancer Immunol Immunother 2009;58:1853-64
20. Huang SM, Bock JM, Harari PM. EpiDermal growth factor receptor blockaDe with C225 moduLates proliferation, apoptosis, and radiosensitivity in squamous cecarcinomas of the head and neck. Cancer Res 1999;59:1935-40
21. Chen DJ, Nirodi CS the epiDermal growth factor receptor: A role in repair of radiation-induced DNA Damage. Clin Cancer Res 2007;13:6555-60
22. Schmitz S, Ang KK, Vermorken J, et al. Targeted therapies for squamous cecarcinoma of the head and neck: current knowledge and future directions. Cancer Treat Rev 2014;40:390-404
23. Sawyers CL the cancer biomarker problem. Nature 2008;452:548-52
24. Kelloff GJ, Sigman CC. Cancer biomarkers: selecting the right drug for the right patient. Nat Rev Drug Discov 2012;11:201-14
25. Schilsky RL. Personalized medicine in oncology: the future is now. Nat Rev Drug Discov 2010;9:363-6
26. Tabatabaeifar S, Kruse TA, Thomassen M, et al. Use of next generation sequencing in head and neck squamous cecarcinomas: A review. Oral Oncol 2014;50(11):1035-40
27. Gregoire V, Lefebvre JL, Licitra L, Felip E. Squamous cecarcinoma of the head and neck: EHNS-ESMO-ESTRO Clinical Practice GuiDelines for diagnosis, treatment and follow-up. Ann Oncol 2010;21(Suppl 5):v184-6
28. Fung C, Grandis JR. Emerging drugs to treat squamous cecarcinomas of the head and neck. Expert Opin Emerg Drugs 2010;15:355-73
29. Dirix P, Nuyts S. EviDence-based organsparing radiotherapy in head and neck cancer. Lancet Oncol 2010;11:85-91
30. Vermorken JB, Herbst RS, Leon X, et al. Overview of the efficacy of cetuximab in recurrent and/or metastatic squamous cecarcinoma of the head and neck in patients who previously failed pLatinumbased therapies. Cancer 2008;112:2710-19
31. Argiris A, Karamouzis MV, Raben D, Ferris RL. Head and neck cancer. Lancet 2008;371:1695-709
32. Overgaard J, Hansen HS, Overgaard M, et al. A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic Larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85. Radiother Oncol 1998;46:135-46
33. Toustrup K, Sorensen BS, Lassen P, et al. Gene expression cLassifier predicts for hypoxic modification of radiotherapy with nimorazole in squamous cecarcinomas of the head and neck. Radiother Oncol 2012;102:122-9
34. Brizel DM, Albers ME, Fisher SR, et al. Hyperfractionated irradiation with or without concurrent chemotherapy for locally adVanced head and neck cancer. N Engl J Med 1998;338:1798-804
35. ADelstein DJ, Li Y, ADams GL, et al. An intergroup phase III comparison of stanDard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cehead and neck cancer. J Clin Oncol 2003;21:92-8
36. Huguenin P, Beer KT, AlLal A, et al. Concomitant cispLatin significantly improves locoregional control in adVanced head and neck cancers treated with hyperfractionated radiotherapy. J Clin Oncol 2004;22:4665-73
37. BuDach V, Stuschke M, BuDach W, et al. Hyperfractionated accelerated chemoradiation with concurrent fluorouracil-mitomycin is more effective than dose-escaLated hyperfractionated accelerated radiation therapy alone in locally adVanced head and neck cancer: final results of the radiotherapy cooperative clinical trials group of the German Cancer Society 95-06 Prospective Randomized Trial. J Clin Oncol 2005;23:1125-35
38. Pignon JP, Bourhis J, Domenge C, Designe L. Chemotherapy adDed to locoregional treatment for head and neck squamous-cecarcinoma: three meta-Analyses of upDated individual Data. MACH-NC ColLaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet 2000;355:949-55
39. Pignon JP, le Maitre A, MailLard E, Bourhis J. Meta-Analysis of chemotherapy in head and neck cancer (MACH-NC): An upDate on 93 randomised trials and 17 ,346 patients. Radiother Oncol 2009;92:4-14
40. Colevas AD. Chemotherapy options for patients with metastatic or recurrent squamous cecarcinoma of the head and neck. J Clin Oncol 2006;24:2644-52
41. Agulnik M. New approaches to EGFR inhibition for locally adVanced or metastatic squamous cecarcinoma of the head and neck (SCCHN). Med Oncol 2012;29:2481-91
42. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for locoregionally adVanced head and neck cancer: 5-year survival Data from a phase 3 randomised trial, and reLation between cetuximab-induced rash and survival. Lancet Oncol 2010;11:21-8
43. Ang KK, Zhang Q, Rosenthal DI, et al. Randomized Phase III trial of concurrent accelerated radiation plus cispLatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522. J Clin Oncol 2014;32(27):2940-50
44. Vermorken JB, Psyrri A, Mesia R, et al. Impact of tumor HPV status on outcome in patients with recurrent and/or metastatic squamous cecarcinoma of the head and neck receiving chemotherapy with or without cetuximab: retrospective analysis of the phase III EXTREME trial. Ann Oncol 2014;25:801-7
45. Baselga J, Trigo JM, Bourhis J, et al. Phase II multicenter study of the antiepiDermal growth factor receptor monoclonal antibody cetuximab in combination with pLatinum-based chemotherapy in patients with pLatinumrefractory metastatic and/or recurrent squamous cecarcinoma of the head and neck. J Clin Oncol 2005;23:5568-77
46. Herbst RS, Arquette M, Shin DM, et al. Phase II multicenter study of the epiDermal growth factor receptor antibody cetuximab and cispLatin for recurrent and refractory squamous cecarcinoma of the head and neck. J Clin Oncol 2005;23:5578-87
47. Wheeler DL, Dunn EF, Harari PM. UnDerstanding resistance to EGFR inhibitors-impact on future treatment strategies. Nat Rev Clin Oncol 2010;7:493-507
48. Keogh B. Era of personalized medicine may herald end of soaring cancer costs. J Natl Cancer Inst 2012;104:12-13; 16-7
49. McCabe C, Bergmann L, Bosanquet N, et al. Market and patient access to new oncology products in Europe: A current, multidisciplinary perspective. Ann Oncol 2009;20:403-12
50. Lurje G, Lenz HJ. EGFR signaling and drug discovery. Oncology 2009;77:400-10
51. Wheeler S, Siwak DR, Chai R, et al. Tumor epiDermal growth factor receptor and EGFR PY1068 are inDepenDent prognostic indicators for head and neck squamous cecarcinoma. Clin Cancer Res 2012;18:2278-89
52. Bentzen SM, Atasoy BM, Daley FM, et al. EpiDermal growth factor receptor expression in pretreatment biopsies from head and neck squamous cecarcinoma as a predictive factor for a benefit from accelerated radiation therapy in a randomized controlled trial. J Clin Oncol 2005;23:5560-7
53. Mountzios G, Rampias T, Psyrri A the mutational spectrum of squamous-cecarcinoma of the head and neck: targetable genetic events and clinical impact. Ann Oncol 2014;25:1889-900
54. Cohen RB. Current challenges and clinical investigations of epiDermal growth factor receptor (EGFR)-And ErbB family-targeted agents in the treatment of head and neck squamous cecarcinoma (HNSCC). Cancer Treat Rev 2014;40:567-77
55. Burtness B, Bauman JE, Galloway T. Novel targets in HPV-negative head and neck cancer: overcoming resistance to EGFR inhibition. Lancet Oncol 2013;14:e302-e09
56. Boeckx C, Baay M, Wouters A, et al. Anti-epiDermal growth factor receptor therapy in head and neck squamous cecarcinoma: focus on potential molecuLar mechanisms of drug resistance. Oncologist 2013;18:850-64
57. Rivera F, Salcedo M, Vega N, et al. Current situation of zalutumumab. Expert Opin Biol Ther 2009;9:667-74
58. Machiels JP, Subramanian S, Ruzsa A, et al. Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cecarcinoma of the head and neck after failure of pLatinum-based chemotherapy: An open-Label, randomised phase 3 trial. Lancet Oncol 2011;12:333-43
59. Yang XD, Jia XC, CorvaLan JR, et al. Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. Crit Rev Oncol Hematol 2001;38:17-23
60. Wirth LJ, Allen AM, Posner MR, et al. Phase I dose-finding study of paclitaxel with panitumumab, carbopLatin and intensity-moduLated radiotherapy in patients with locally adVanced squamous cecancer of the head and neck. Ann Oncol 2010;21:342-7
61. Vermorken JB, Stohlmacher-Williams J, DaviDenko I, et al. CispLatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cecarcinoma of the head and neck (SPECTRUM): An open-Label phase 3 randomised trial. Lancet Oncol 2013;14:697-710
62. Ramakrishnan MS, Eswaraiah A, Crombet T, et al. Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin. MAbs 2009;1:41-8
63. Crombet T, Osorio M, Cruz T, et al. Use of the humanized anti-epiDermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally adVanced head and neck cancer patients. J Clin Oncol 2004;22:1646-54
64. Rodriguez MO, Rivero TC, Del Castillo Bahi R, et al. Nimotuzumab plus radiotherapy for unresectable squamous-cecarcinoma of the head and neck. Cancer Biol Ther 2010;9:343-9
65. Basavaraj C, Sierra P, Shivu J, et al. Nimotuzumab with chemoradiation confers a survival adVantage in treatmentnaive head and neck tumors over expressing EGFR. Cancer Biol Ther 2010;10:673-81
66. Kamath AV, Lu D, Gupta P, et al. Preclinical pharmacokinetics of MEHD7945A, a novel EGFR/HER3 dual-Action antibody, and prediction of its human pharmacokinetics and efficacious clinical dose. Cancer Chemother Pharmacol 2012;69:1063-9
67. Schaefer G, Haber L, Crocker LM, et al. A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies. Cancer Ce2011;20:472-86
68. Stewart JS, Cohen EE, Licitra L, et al. Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cecarcinoma of the head and neck [corrected]. J Clin Oncol 2009;27:1864-71
69. Argiris A, Ghebremichael M, Gilbert J, et al. Phase III randomized, pLacebocontrolled trial of docetaxel with or without gefitinib in recurrent or metastatic head and neck cancer: An eastern cooperative oncology group trial. J Clin Oncol 2013;31:1405-14
70. Soulieres D, Senzer NN, Vokes EE, et al. Multicenter phase II study of erlotinib, an oral epiDermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cecancer of the head and neck. J Clin Oncol 2004;22:77-85
71. Martins RG, Parvathaneni U, Bauman JE, et al. CispLatin and radiotherapy with or without erlotinib in locally adVanced squamous cecarcinoma of the head and neck: A randomized phase II trial. J Clin Oncol 2013;31:1415-21
72. Harrington K, Berrier A, Robinson M, et al. Randomised Phase II study of oral Lapatinib combined with chemoradiotherapy in patients with adVanced squamous cecarcinoma of the head and neck: rationale for future randomised trials in human papilloma virus-negative disease. Eur J Cancer 2013;49:1609-18
73. Del Campo JM, Hitt R, Sebastian P, et al. Effects of Lapatinib monotherapy: results of a randomised phase II study in therapy-naive patients with locally adVanced squamous cecarcinoma of the head and neck. Br J Cancer 2011;105:618-27
74. De Souza JA, Davis DW, Zhang Y, et al. A phase II study of Lapatinib in recurrent/metastatic squamous cecarcinoma of the head and neck. Clin Cancer Res 2012;18:2336-43
75. Seiwert TY, Fayette J, Cupissol D, et al. A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cecarcinoma of the head and neck. Ann Oncol 2014;25:1813-20
76. Abdul Razak AR, Soulieres D, Laurie SA, et al. A phase II trial of Dacomitinib, an oral pan-human EGF receptor (HER) inhibitor, as first-line treatment in recurrent and/or metastatic squamous-cecarcinoma of the head and neck. Ann Oncol 2013;24:761-9
77. Trusolino L, Bertotti A, Comoglio PM. MET signalling: principles and functions in Development, organ regeneration and cancer. Nat Rev Mol CeBiol 2010;11:834-48
78. Patnaik A, Weiss GJ, Papadopoulos KP, et al. Phase I ficLatuzumab monotherapy or with erlotinib for refractory adVanced solid tumours and multiple myeloma. Br J Cancer 2014;111:272-80
79. Tabernero J, Elez ME, Herranz M, et al. A pharmacodynamic/pharmacokinetic study of ficLatuzumab in patients with adVanced solid tumors and liver metastases. Clin Cancer Res 2014;20:2793-804
80. Mittra ES, Fan-Minogue H, Lin FI, et al. Preclinical efficacy of the antihepatocyte growth factor antibody ficLatuzumab in a mouse brain orthotopic glioma moDel evaluated by bioluminescence, PET, and MRI. Clin Cancer Res 2013;19:5711-21
81. Turke AB, ZejnulLahu K, Wu YL, et al. Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Ce2010;17:77-88
82. Agarwal S, Zerillo C, Kolmakova J, et al. Association of constitutively activated hepatocyte growth factor receptor (Met) with resistance to a dual EGFR/Her2 inhibitor in non-small-celung cancer cells. Br J Cancer 2009;100:941-9
83. BeneDettini E, ShoLM, Peyton M, et al. Met activation in non-smacelung cancer is associated with De novo resistance to EGFR inhibitors and the Development of brain metastasis. Am J Pathol 2010;177:415-23
84. Seiwert TY, JagaDeeswaran R, Faoro L, et al the MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cecarcinoma. Cancer Res 2009;69:3021-31
85. Sun S, Wang Z. Head neck squamous cecarcinoma c-Met(+) cells dispLay cancer stem ceproperties and are responsible for cispLatin-resistance and metastasis. Int J Cancer 2011;129:2337-48
86. Chau NG, Perez-Ordonez B, Zhang K, et al the association between EGFR variant III, HPV, p16, c-MET, EGFR gene copy number and response to EGFR inhibitors in patients with recurrent or metastatic squamous cecarcinoma of the head and neck. Head Neck Oncol 2011;3:11
87. Seiwert T, Sarantopoulos J, KallenDer H, et al. Phase II trial of single-Agent foretinib (GSK1363089) in patients with recurrent or metastatic squamous cecarcinoma of the head and neck. Invest New Drugs 2013;31:417-24
88. Baserga R the insulin-like growth factor-I receptor as a target for cancer therapy. Expert Opin Ther Targets 2005;9:753-68
89. Barnes CJ, Ohshiro K, RayaLa SK, et al. Insulin-like growth factor receptor as a therapeutic target in head and neck cancer. Clin Cancer Res 2007;13:4291-9
90. Thariat J, Bensadoun RJ, Etienne-Grimaldi MC, et al. Contrasted outcomes to gefitinib on tumoral IGF1R expression in head and neck cancer patients receiving postoperative chemoradiation (GORTEC trial 2004-02). Clin Cancer Res 2012;18:5123-33
91. Schmitz S, Kaminsky-Forrett MC, Henry S, et al. Phase II study of figitumumab in patients with recurrent and/or metastatic squamous cecarcinoma of the head and neck: clinical activity and molecuLar response (GORTEC 2008-02). Ann Oncol 2012;23:2153-61
92. Kerbel RS. Tumor angiogenesis. N Engl J Med 2008;358:2039-49
93. Gerber PA, Hippe A, Buhren BA, et al. Chemokines in tumor-Associated angiogenesis. Biol Chem 2009;390:1213-23
94. Gacche RN, Meshram RJ. Angiogenic factors as potential drug target: efficacy and l mitations of anti-Angiogenic therapy. Biochim Biophys Acta 2014;1846:161-79
95. Kyzas PA, Cunha IW, Ioannidis JP. Prognostic significance of vascuLar endothelial growth factor immunohistochemical expression in head and neck squamous cecarcinoma: A meta-Analysis. Clin Cancer Res 2005;11:1434-40
96. Neuchrist C, Erovic BM, Handisurya A, et al. VascuLar endothelial growth factor C and vascuLar endothelial growth factor receptor 3 expression in squamous cecarcinomas of the head and neck. Head Neck 2003;25:464-74
97. Goel HL, Mercurio AM. VEGF targets the tumour cell. Nat Rev Cancer 2013;13:871-82
98. Ferrara N, HilLan KJ, Gerber HP, Novotny W. Discovery and Development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004;3:391-400
99. Fury MG, Lee NY, Sherman E, et al. A phase 2 study of bevacizumab with cispLatin plus intensity-moduLated radiation therapy for stage III/IVB head and neck squamous cecancer. Cancer 2012;118:5008-14
100. Argiris A, Kotsakis AP, Hoang T, et al. Cetuximab and bevacizumab: preclinical Data and phase II trial in recurrent or metastatic squamous cecarcinoma of the head and neck. Ann Oncol 2013;24:220-5
101. Argiris A, Karamouzis MV, Gooding WE, et al. Phase II trial of pemetrexed and bevacizumab in patients with recur ent or metastatic head and neck cancer. J Clin Oncol 2011;29:1140-5
102. Machiels JP, Henry S, Zanetta S, et al. Phase II study of sunitinib in recurrent or metastatic squamous cecarcinoma of the head and neck: GORTEC 2006-01. J Clin Oncol 2010;28:21-8
103. Choong NW, Kozloff M, Taber D, et al. Phase II study of sunitinib maLate in head and neck squamous cecarcinoma. Invest New Drugs 2010;28:677-83
104. FountziLas G, Fragkoulidi A, Kalogera-FountziLa A, et al. A phase II study of sunitinib in patients with recurrent and/or metastatic nonnasopharyngeal head and neck cancer. Cancer Chemother Pharmacol 2010;65:649-60
105. Williamson SK, Moon J, Huang CH, et al. Phase II evaluation of sorafenib in adVanced and metastatic squamous cecarcinoma of the head and neck: southwest Oncology Group Study S0420. J Clin Oncol 2010;28:3330-5
106. Kim LC, Song L, Haura EB. Src kinases as therapeutic targets for cancer. Nat Rev Clin Oncol 2009;6:587-95
107. Koppikar P, Choi SH, Egloff AM, et al. Combined inhibition of c-Src and epiDermal growth factor receptor abrogates growth and invasion of head and neck squamous cecarcinoma. Clin Cancer Res 2008;14:4284-91
108. Johnson FM, Saigal B, Talpaz M, Donato NJ. Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cecycle arrest and apoptosis of head and neck squamous cecarcinoma and non-smacelung cancer cells. Clin Cancer Res 2005;11:6924-32
109. Li C, IiDa M, Dunn EF, Wheeler DL. Dasatinib blocks cetuximab-And radiation-induced nuclear translocation of the epiDermal growth factor receptor in head and neck squamous cecarcinoma. Radiother Oncol 2010;97:330-7
110. Raju U, Riesterer O, Wang ZQ, et al. Dasatinib, a multi-kinase inhibitor increased radiation sensitivity by interfering with nuclear localization of epiDermal growth factor receptor and by blocking DNA repair pathways. Radiother Oncol 2012;105:241-9
111. Brooks HD, Glisson BS, Bekele BN, et al. Phase 2 study of Dasatinib in the treatment of head and neck squamous cecarcinoma. Cancer 2011;117:2112-19
112. Molinolo AA, Hewitt SM, Amornphimoltham P, et al. Dissecting the Akt/mammalian target of rapamycin signaling network: emerging results from the head and neck cancer tissue array initiative. Clin Cancer Res 2007;13:4964-73
113. Freudlsperger C, Burnett JR, Friedman JA, et al. EGFR-PI3K-AKTmTOR signaling in head and neck squamous cecarcinomas: Attractive targets for molecuLar-oriented therapy. Expert Opin Ther Targets 2011;15:63-74
114. Casse A, Freilino ML, Lee J, et al. Targeting TORC1/2 enhances sensitivity to EGFR inhibitors in head and neck cancer preclinical moDels. NeopLasia 2012;14:1005-14
115. Bozec A, Etienne-Grimaldi MC, Fischel JL, et al the mTOR-targeting drug temsirolimus enhances the growthinhibiting effects of the cetuximab-bevacizumab-irradiation combination on head and neck cancer xenografts. Oral Oncol 2011;47:340-4
116. Bali A, Bali D, Sharma A. An overview of gene therapy in head and neck cancer. Indian J Hum Genet 2013;19:282-90
117. Kandoth C, McLelLan MD, Vandin F, et al. Mutational Landscape and significance across 12 major cancer types. Nature 2013;502:333-9
118. Chen GX, Zhang S, He XH, et al. Clinical utility of recombinant aDenoviral human p53 gene therapy: current perspectives. Onco Targets Ther 2014;7:1901-9
119. Han DM, Huang ZG, Zhang W, et al. Effectiveness of recombinant aDenovirus p53 injection on Laryngeal cancer: phase I clinical trial and follow up. Zhonghua Yi Xue Za Zhi 2003;83:2029-32
120. Chen CB, Pan JJ, Xu LY. Recombinant aDenovirus p53 agent injection combined with radiotherapy in treatment of nasopharyngeal carcinoma: A phase II clinical trial. Zhonghua Yi Xue Za Zhi 2003;83:2033-5
121. Zhang SW, Xiao SW, Liu CQ, et al. Recombinant aDenovirus-p53 gene therapy combined with radiotherapy for head and neck squamous-cecarcinoma. Zhonghua Zhong Liu Za Zhi 2005;27:426-8
122. Zhang SW, Xiao SW, Liu CQ, et al. Treatment of head and neck squamous cecarcinoma by recombinant aDenovirus-p53 combined with radiotherapy: A phase II clinical trial of 42 cases. Zhonghua Yi Xue Za Zhi 2003;83:2023-8
123. Wills KN, Maneval DC, Menzel P, et al. Development and characterization of recombinant aDenoviruses encoding human p53 for gene therapy of cancer. Hum Gene Ther 1994;5:1079-88
124. Gabrilovich DI. INGN 201 (Advexin): ADenoviral p53 gene therapy for cancer. Expert Opin Biol Ther 2006;6:823-32
125. Tazawa H, Kagawa S, Fujiwara T. AdVances in aDenovirus-mediated p53 cancer gene therapy. Expert Opin Biol Ther 2013;13:1569-83
126. Khuri FR, Nemunaitis J, Ganly I, et al. a controlled trial of intratumoral ONYX-015, a selectively-replicating aDenovirus, in combination with cispLatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med 2000;6:879-85
127. Nemunaitis J, Khuri F, Ganly I, et al. Phase II trial of intratumoral administration of ONYX-015, a replication-selective aDenovirus, in patients with refractory head and neck cancer. J Clin Oncol 2001;19:289-98
128. Yu W, Fang H. Clinical trials with oncolytic aDenovirus in China. Curr Cancer Drug Targets 2007;7:141-8
129. Xia ZJ, Chang JH, Zhang L, et al. Phase III randomized clinical trial of intratumoral injection of E1B geneDeleted aDenovirus (H101) combined with cispLatin-based chemotherapy in treating squamous cecancer of head and neck or esophagus. Ai Zheng 2004;23:1666-70
130. Niwa H, Wentzel AL, Li M, et al. Antitumor effects of epiDermal growth factor receptor antisense oligonucleotiDes in combination with docetaxel in squamous cecarcinoma of the head and neck. Clin Cancer Res 2003;9:5028-35
131. Lai SY, Koppikar P, Thomas SM, et al. Intratumoral epiDermal growth factor receptor antisense DNA therapy in head and neck cancer: first human application and potential antitumor mechanisms. J Clin Oncol 2009;27:1235-42
132. Duray A, Demoulin S, Hubert P, et al. Immune suppression in head and neck cancers: A review. Clin Dev Immunol 2010;2010:701657
133. Alhamarneh O, Amarnath SM, Stafford ND, Greenman J. ReguLatory T cells: what role do they pLay in antitumor immunity in patients with head and neck cancer? Head Neck 2008;30:251-61
134. WhitesiDe TL. Anti-tumor vaccines in head and neck cancer: targeting immune responses to the tumor. Curr Cancer Drug Targets 2007;7:633-42
135. VarilLa V, Atienza J, Dasanu CA. Immune alterations and immunotherapy prospects in head and neck cancer. Expert Opin Biol Ther 2013;13:1241-56
136. Schutt C, Bumm K, MirandoLa L, et al. Immunological treatment options for locoregionally adVanced head and neck squamous cecarcinoma. Int Rev Immunol 2012;31:22-42
137. Chen J, Feng Y, Lu L, et al. Interferon-gamma-induced PD-L1 surface expression on human oral squamous carcinoma via PKD2 signal pathway. Immunobiology 2012;217:385-93
138. Chemnitz JM, Parry RV, Nichols KE, et al. SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed Death 1 upon primary human T cestimuLation, but only receptor ligation prevents T ceactivation. J Immunol 2004;173:945-54
139. Cho YA, Yoon HJ, Lee JI, et al. ReLationship between the expressions of PD-L1 and tumor-infiltrating lymphocytes in oral squamous cecarcinoma. Oral Oncol 2011;47:1148-53
140. Wolf GT, Fee WE Jr, DoLan RW, et al. Novel neoadjuVant immunotherapy regimen safety and survival in head and neck squamous cecancer. Head Neck 2011;33:1666-74
141. ErjaLa K, SundvaM, JunttiLa TT, et al. Signaling via ErbB2 and ErbB3 associates with resistance and epiDermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cecarcinoma cells. Clin Cancer Res 2006;12:4103-11
142. Han SW, Kim TY, Hwang PG, et al. Predictive and prognostic impact of epiDermal growth factor receptor mutation in non-small-celung cancer patients treated with gefitinib. J Clin Oncol 2005;23:2493-501
143. Lievre A, Bachet JB, Le Corre D, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006;66:3992-5
144. Fakhry C, Westra WH, Li S, et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cecarcinoma in a prospective clinical trial. J Natl Cancer Inst 2008;100:261-9
145. Stransky N, Egloff AM, Tward AD, et al the mutational Landscape of head and neck squamous cecarcinoma. Science 2011;333:1157-60
146. Lui VW, Hedberg ML, Li H, et al. Frequent mutation of the PI3K pathway in head and neck cancer Defines predictive biomarkers. Cancer Discov 2013;3:761-9
147. Agrawal N, FreDerick MJ, Pickering CR, et al. Exome sequencing of head and neck squamous cecarcinoma reveals inactivating mutations in NOTCH1. Science 2011;333:1154-7
148. Pickering CR, Zhang J, Yoo SY, et al. Integrative genomic characterization of oral squamous cecarcinoma iDentifies frequent somatic drivers. Cancer Discov 2013;3:770-81
149. Cancer Genome AtLas Research N. Weinstein JN, Collisson EA, Mills GB, et al the Cancer Genome AtLas Pan-Cancer analysis project. Nat Genet 2013;45:1113-20